<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002504</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000077942</org_study_id>
    <secondary_id>CBRG-9211</secondary_id>
    <secondary_id>NBSG-9211</secondary_id>
    <secondary_id>NCI-V92-0148</secondary_id>
    <nct_id>NCT00002504</nct_id>
  </id_info>
  <brief_title>Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer</brief_title>
  <official_title>OUTPATIENT SUBCUTANEOUS IL-2 AND ALPHA INTERFERON IN THE MANAGEMENT OF METASTATIC CANCER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoag Memorial Hospital Presbyterian</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Biotherapy Research Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoag Memorial Hospital Presbyterian</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill metastatic cancer
      cells. Interferon alfa may interfere with the growth of the cancer cells. Combining
      interleukin-2 and interferon alfa may kill more cancer cells.

      PURPOSE: Phase II trial to study the effectiveness of interleukin-2 plus interferon alfa in
      treating adults with metastatic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the response rate, failure-free survival, and overall survival of
      interleukin-2 and interferon alpha administered subcutaneously on an outpatient basis for 8
      weeks to patients with metastatic cancer. II. Determine the toxicities associated with this
      therapy.

      OUTLINE: Biological Response Modifier Therapy. Interleukin-2 (Cetus), IL-2, NSC-373364;
      Interferon alpha (Schering), IFN-A, NSC-377523.

      PROJECTED ACCRUAL: Up to 30 patients with various malignancies will be entered.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1992</start_date>
  <completion_date type="Actual">February 1999</completion_date>
  <primary_completion_date type="Actual">February 1998</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Precancerous/Nonmalignant Condition</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed metastatic cancer of any type Measurable
        or evaluable disease required, i.e.: Bidimensionally measurable lesions on physical exam,
        x-ray, CT, MRI, or other radiologic procedure Any lesion apparent on radiologic exam that
        is not measurable in 2 perpendicular diameters Previously irradiated lesions acceptable
        provided subsequent progression is documented No active brain metastases Previously treated
        brain metastases allowed provided measurable/evaluable disease exists outside the CNS

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Hematopoietic:
        (within 14 days prior to entry) WBC at least 3,000 Platelets at least 100,000 Hematocrit at
        least 30% (may be transfused) Hepatic: (within 14 days prior to entry) Bilirubin less than
        2.0 mg/dl PT and PTT normal Renal: (within 14 days prior to entry) Creatinine less than 2.0
        mg/dl Cardiovascular: No MI within 6 months No medication for arrhythmia No medication for
        CHF Hypertension that is stable off medication allowed Pulmonary: pO2 at least 60 mm Hg in
        patients with primary lung cancer or symptomatic pulmonary disease Reasonable respiratory
        reserve No dyspnea at rest No requirement for supplemental oxygen Other: No familial
        history of malignant hyperthermia No chronic underlying immunodeficiency disease No HIV
        seropositivity No active infection requiring antibiotic therapy No other serious
        intercurrent illness No concurrent malignancy No pregnant or nursing women Adequate
        contraception required of fertile women

        PRIOR CONCURRENT THERAPY: No concurrent therapy with other anticancer agents No concurrent
        immunosuppressive agents (e.g., cyclosporin) Biologic therapy: Prior interferon alpha
        allowed Chemotherapy: At least 4 weeks since systemic chemotherapy with recovery required
        Endocrine therapy: No concurrent corticosteroids Radiotherapy: At least 4 weeks since
        radiotherapy Surgery: Adequate recovery required Other: No prior organ allograft
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert O. Dillman, MD, FACP</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Biotherapy Research Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bloomington Hospital</name>
      <address>
        <city>Bloomington</city>
        <state>Indiana</state>
        <zip>47402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital and Health Care Center Research Department</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bergan Mercy Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Regional Cancer Center - Knoxville</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Dillman RO, Soori G, Tai DF, et al.: Outpatient subcutaneous (SC) interleukin-2 (IL-2) and interferon alpha (IFN) in the management of metastatic cancer: a preliminary report. J Immunother 20(5): 404, 1997.</citation>
  </results_reference>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>July 23, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2004</study_first_posted>
  <last_update_submitted>May 10, 2011</last_update_submitted>
  <last_update_submitted_qc>May 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Robert O. Dillman, MD</name_title>
    <organization>Hoag Memorial Hospital Presbyterian</organization>
  </responsible_party>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>monoclonal gammopathy of undetermined significance</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>isolated plasmacytoma of bone</keyword>
  <keyword>extramedullary plasmacytoma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>meningeal chronic myelogenous leukemia</keyword>
  <keyword>untreated adult acute lymphoblastic leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>polycythemia vera</keyword>
  <keyword>chronic idiopathic myelofibrosis</keyword>
  <keyword>essential thrombocythemia</keyword>
  <keyword>untreated hairy cell leukemia</keyword>
  <keyword>progressive hairy cell leukemia, initial treatment</keyword>
  <keyword>refractory hairy cell leukemia</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>T-cell large granular lymphocyte leukemia</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>primary systemic amyloidosis</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

